Methylphenidate Generis
Extended-release methylphenidate hydrochloride 18 mg tablets for ADHD
Quick Facts: Methylphenidate Generis
Key Takeaways
- Extended-release formulation: Provides controlled symptom relief for up to 10-12 hours with a single morning dose, reducing the need for multiple daily administrations
- Do not crush or chew: The tablets must be swallowed whole to maintain the controlled-release mechanism; breaking the tablet can cause dangerous immediate release of the full dose
- Cardiovascular monitoring required: Blood pressure and heart rate should be checked regularly before and during treatment, as methylphenidate can increase both
- Growth monitoring in children: Long-term use may affect height and weight gain; regular growth assessments are recommended for pediatric patients
- Part of comprehensive ADHD treatment: Methylphenidate works best as part of a multimodal treatment plan that includes behavioral therapy, educational support, and psychological counseling
What Is Methylphenidate Generis and What Is It Used For?
Methylphenidate Generis is an extended-release central nervous system stimulant containing methylphenidate hydrochloride 18 mg, prescribed primarily for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 and older, adolescents, and adults. It works by increasing dopamine and norepinephrine levels in the brain to improve focus, attention, and impulse control.
Methylphenidate hydrochloride belongs to a class of medications known as central nervous system (CNS) stimulants. Despite the name "stimulant," in individuals with ADHD, the medication has a paradoxical calming and focusing effect. It works by blocking the reuptake of two key neurotransmitters — dopamine and norepinephrine — in the prefrontal cortex, the brain region primarily responsible for executive functions such as attention, planning, decision-making, and impulse control.
The Generis formulation uses an osmotic-release oral system (OROS) technology in its extended-release tablets. This advanced delivery mechanism consists of an outer drug coating that provides an initial dose within the first hour, followed by an osmotic pump that gradually pushes the remaining medication through a laser-drilled opening in the tablet over a period of 10 to 12 hours. This mimics the pharmacokinetic profile of multiple immediate-release doses throughout the day while requiring only a single morning administration.
ADHD is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. According to the World Health Organization (WHO), ADHD affects approximately 5-7% of children and 2.5-4% of adults worldwide. The condition is recognized as a legitimate medical diagnosis by every major medical, psychological, and educational organization globally, including the American Psychiatric Association (APA), the European Medicines Agency (EMA), and the National Institute for Health and Care Excellence (NICE).
In addition to ADHD, methylphenidate may also be prescribed for narcolepsy, a chronic neurological condition characterized by excessive daytime sleepiness and sudden sleep attacks. However, the Generis extended-release formulation is primarily indicated for ADHD treatment as part of a comprehensive management program that typically includes psychological, educational, and social measures.
Methylphenidate Generis manages the symptoms of ADHD but does not cure the underlying condition. It should be used as part of a comprehensive treatment plan that may include behavioral therapy, educational accommodations, parent training, and lifestyle modifications. The need for continued treatment should be regularly reassessed by the prescribing physician, typically at least once per year.
What Should You Know Before Taking Methylphenidate Generis?
Before starting Methylphenidate Generis, a thorough medical evaluation is required including cardiovascular assessment, psychiatric history, and screening for substance abuse risk. The medication is contraindicated in patients with glaucoma, pheochromocytoma, hyperthyroidism, severe cardiovascular disorders, and concurrent MAO inhibitor use.
Methylphenidate Generis requires a thorough medical evaluation before treatment begins. The prescribing physician must conduct a comprehensive assessment that includes a detailed medical history, cardiovascular evaluation (including blood pressure and heart rate measurement), psychiatric assessment, and review of current medications. A proper diagnosis of ADHD should be established according to established diagnostic criteria (DSM-5 or ICD-11) before initiating pharmacological treatment.
Contraindications
Methylphenidate Generis must not be used in the following situations:
- Known hypersensitivity to methylphenidate or any of the excipients in the formulation
- Glaucoma (increased intraocular pressure) — methylphenidate can further elevate eye pressure
- Pheochromocytoma — a rare adrenal gland tumor; methylphenidate may trigger a hypertensive crisis
- Hyperthyroidism or thyrotoxicosis — stimulant effects may exacerbate thyroid-related symptoms
- Severe cardiovascular disorders including uncontrolled hypertension, heart failure, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathy, recent myocardial infarction, life-threatening arrhythmias, and channelopathies
- Concurrent use of monoamine oxidase (MAO) inhibitors, or within 14 days of discontinuing an MAO inhibitor, due to the risk of hypertensive crisis
- Existing diagnosis of severe depression, anorexia nervosa, psychotic symptoms, suicidal tendencies, severe mood disorders, or mania
- Known drug or alcohol dependence due to the abuse potential of stimulant medications
Warnings and Precautions
Several clinical situations require special caution and close monitoring during methylphenidate treatment:
Cardiovascular effects: Methylphenidate can increase blood pressure (typically 2-4 mmHg) and heart rate (typically 3-6 bpm). Patients with pre-existing hypertension, heart conditions, or structural cardiac abnormalities should be carefully monitored. Sudden death has been reported in rare cases in patients with pre-existing structural cardiac abnormalities or other serious heart problems taking stimulant medications. A baseline cardiovascular assessment, including blood pressure and heart rate, should be performed before treatment initiation and at every dose adjustment.
Psychiatric effects: Methylphenidate may exacerbate symptoms of behavioral disturbances and thought disorders in patients with pre-existing psychotic conditions. It may induce new psychotic or manic symptoms in patients without a prior history. Treatment-emergent psychiatric symptoms such as hallucinations, delusional thinking, or mania require immediate medical evaluation and consideration of discontinuation. Patients with comorbid bipolar disorder require particularly careful management, as stimulants may precipitate a manic episode.
Growth suppression: Long-term use of methylphenidate in children has been associated with moderate reductions in weight gain and growth velocity. Current evidence suggests that growth reduction is modest (approximately 1-2 cm reduction in expected height after 3 years of continuous use), and growth tends to normalize after treatment discontinuation or during drug holidays. Height, weight, and appetite should be monitored at least every 6 months during treatment.
Seizure risk: Methylphenidate may lower the seizure threshold. In patients with a history of seizures or epilepsy, careful clinical monitoring is required. If seizure frequency increases, methylphenidate should be discontinued.
Abuse potential: Methylphenidate is a Schedule II controlled substance (in the US and UK) with recognized potential for misuse, abuse, and dependence. The extended-release formulation reduces but does not eliminate this risk. Patients with a history of substance use disorders should be carefully assessed before and during treatment. Signs of misuse or diversion should prompt treatment re-evaluation.
Pregnancy and Breastfeeding
Methylphenidate Generis should not be used during pregnancy unless the potential benefit clearly outweighs the potential risk to the fetus. Animal studies have shown evidence of teratogenicity at high doses, although human data are limited. A small number of retrospective studies have not identified a clear pattern of major congenital malformations, but cardiovascular malformations have been reported. Women of childbearing potential should discuss contraception options with their physician before initiating treatment.
Methylphenidate is excreted in breast milk. The concentration in breast milk is low, and the calculated infant dose is less than 1% of the maternal weight-adjusted dose. However, individual variation exists, and the decision to breastfeed during methylphenidate treatment should be made in consultation with the prescribing physician, weighing the benefits of breastfeeding and the potential risks to the infant.
Do not suddenly stop taking Methylphenidate Generis without consulting your physician. Although methylphenidate does not produce the severe physical withdrawal seen with some other substances, abrupt discontinuation can lead to rebound symptoms including increased hyperactivity, irritability, fatigue, and depressed mood. Your physician will advise on gradual dose reduction if discontinuation is needed.
How Does Methylphenidate Generis Interact with Other Drugs?
Methylphenidate has clinically significant interactions with MAO inhibitors (contraindicated), antihypertensive agents, coumarin anticoagulants, anticonvulsants, and certain antidepressants. It may also interact with anesthetic agents and alcohol. Always inform your physician of all medications, supplements, and herbal products you are taking.
Drug interactions are an important consideration when using Methylphenidate Generis. Methylphenidate's primary pharmacological actions — dopamine and norepinephrine reuptake inhibition — can interact with other medications that affect catecholaminergic neurotransmission, blood pressure regulation, or hepatic drug metabolism. While methylphenidate is not extensively metabolized by cytochrome P450 enzymes (it is primarily metabolized by carboxylesterase CES1A1), it can still affect the metabolism and effects of several drug classes.
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| MAO Inhibitors (e.g., phenelzine, tranylcypromine, selegiline) | Risk of hypertensive crisis due to potentiated catecholamine effects | Contraindicated. Do not use within 14 days of MAO inhibitor use. |
| Coumarin anticoagulants (e.g., warfarin) | Methylphenidate may inhibit metabolism of coumarins, increasing anticoagulant effect and bleeding risk | Monitor INR closely when starting, stopping, or adjusting methylphenidate dose. Warfarin dose adjustment may be needed. |
| Anticonvulsants (e.g., phenytoin, phenobarbital, primidone) | Methylphenidate may inhibit metabolism of anticonvulsants, leading to increased serum levels and toxicity risk | Monitor anticonvulsant levels and adjust doses accordingly. Watch for signs of toxicity. |
| Vasopressor agents (e.g., dopamine, norepinephrine) | Enhanced pressor response due to additive catecholaminergic effects | Use with extreme caution. Monitor blood pressure and heart rate closely in surgical/emergency settings. |
Other Notable Interactions
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Antihypertensive agents | Methylphenidate may reduce the effectiveness of blood pressure-lowering medications | Monitor blood pressure; antihypertensive dose adjustment may be required. |
| SSRIs / SNRIs (e.g., fluoxetine, sertraline, venlafaxine) | Potential for increased serotonergic activity; rare reports of serotonin syndrome | Monitor for signs of serotonin syndrome (agitation, confusion, rapid heart rate, hyperthermia). |
| Tricyclic antidepressants (e.g., imipramine, desipramine) | Methylphenidate may increase plasma levels of tricyclics | Monitor for tricyclic side effects; dose reduction may be needed. |
| Halogenated anesthetics | Risk of sudden blood pressure increase during surgery | Discontinue methylphenidate on the day of planned surgery using halogenated anesthetics. |
| Alcohol | May worsen CNS side effects; may alter release profile of extended-release formulation | Avoid alcohol during treatment. |
| Dopaminergic drugs (e.g., antipsychotics) | Mutual antagonism of therapeutic effects | Carefully evaluate risk-benefit of combination therapy. |
What Is the Correct Dosage of Methylphenidate Generis?
Methylphenidate Generis 18 mg extended-release tablets should be taken once daily in the morning, swallowed whole with water. Dosing is individualized and typically starts at the lowest available dose, with gradual titration based on clinical response and tolerability. The maximum recommended daily dose is 54 mg for children and 72 mg for adults.
Dosing of Methylphenidate Generis must be individualized according to the therapeutic needs and response of the patient. Treatment should be initiated under the supervision of a specialist in behavioral disorders in children and/or adolescents, or by a psychiatrist or neurologist experienced in ADHD management. The goal is to find the lowest effective dose that provides adequate symptom control with acceptable tolerability.
Children (6 years and older) and Adolescents
Pediatric Dosing Guidelines
- Starting dose: 18 mg once daily in the morning
- Dose titration: May increase in increments of 18 mg at weekly intervals based on response and tolerability
- Maximum dose: 54 mg once daily (or 2 mg/kg/day, whichever is lower)
- Switching from immediate-release: Patients currently on methylphenidate IR can switch to the nearest equivalent total daily dose of the ER formulation
It is essential that methylphenidate treatment in children is initiated only after a comprehensive assessment confirms the ADHD diagnosis. Non-pharmacological interventions should be considered as first-line treatment for mild-to-moderate ADHD, as recommended by NICE guidelines (2018, updated 2024). When medication is indicated, the starting dose should always be the lowest available, with careful upward titration. Clinical response should be evaluated within 1-4 weeks of dose adjustment.
Adults
Adult Dosing Guidelines
- Starting dose: 18 mg once daily in the morning
- Dose titration: May increase by 18 mg per week based on response and tolerability
- Usual maintenance dose: 18–54 mg once daily
- Maximum dose: 72 mg once daily (some guidelines permit up to 108 mg in specialist settings)
Adult ADHD diagnosis requires documented symptom onset in childhood (before age 12 per DSM-5, or before age 7 per ICD-10) with current functional impairment. For adults initiating treatment de novo, the same cautious titration approach applies. Adults may require higher absolute doses than children due to increased body weight, but the lowest effective dose principle remains paramount. Cardiovascular monitoring is particularly important in adult patients, who may have accumulated additional cardiovascular risk factors.
Elderly Patients
Elderly Dosing Considerations
Methylphenidate Generis should not be initiated in patients over 65 years of age. There is insufficient clinical data on the safety and efficacy of methylphenidate in this population. Elderly patients are more susceptible to cardiovascular adverse effects, and the risk-benefit ratio has not been established. For elderly patients already on stable methylphenidate therapy who are aging into this category, continued treatment should be regularly reassessed with particular attention to cardiovascular health.
Missed Dose
If you miss a dose of Methylphenidate Generis, take it as soon as you remember, provided it is still morning. Because of the extended-release nature of the medication (lasting 10-12 hours), taking the tablet in the afternoon may cause insomnia and sleep disturbance. If it is already past noon, skip the missed dose entirely and take the next dose at the usual time the following morning. Never take a double dose to make up for a missed one.
Overdose
Signs of methylphenidate overdose include: agitation, tremors, muscle twitching, convulsions, euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperthermia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dry mouth. In severe cases, overdose can lead to coma, circulatory collapse, and death. There is no specific antidote for methylphenidate overdose. Treatment is supportive and symptomatic. Contact your local poison control center or emergency services immediately.
The extended-release formulation adds a particular concern in overdose situations because the osmotic-release mechanism continues to deliver medication over an extended period. This means that even if the patient appears stable initially, delayed deterioration is possible. Extended monitoring (minimum 24 hours) is recommended following overdose with extended-release methylphenidate formulations. Activated charcoal may be considered if the ingestion was recent, but its efficacy is limited due to the controlled-release design of the tablet.
- Take once daily in the morning, with or without food
- Swallow the tablet whole with a full glass of water
- Never crush, chew, or split the extended-release tablet
- The tablet shell may appear in stool — this is normal and does not affect drug absorption
- Maintain consistent daily timing for optimal results
What Are the Side Effects of Methylphenidate Generis?
The most common side effects of Methylphenidate Generis include decreased appetite, insomnia, headache, dry mouth, nausea, and nervousness. Most side effects are dose-dependent and tend to diminish over time. Serious but rare adverse effects include cardiovascular events, psychiatric symptoms, and growth suppression in children.
Like all medications, Methylphenidate Generis can cause side effects, although not everyone experiences them. Clinical trials and post-marketing surveillance have identified a range of adverse reactions organized by frequency. Understanding the relative likelihood of side effects can help patients and caregivers make informed decisions and recognize symptoms that require medical attention. The following frequency classification follows the standard conventions used by the European Medicines Agency (EMA):
Very Common (affects more than 1 in 10 people)
- Decreased appetite and reduced food intake
- Insomnia (difficulty falling asleep or staying asleep)
- Headache
- Dry mouth
- Nervousness and restlessness
Common (affects 1 to 10 in 100 people)
- Nausea, vomiting, abdominal pain
- Dizziness
- Tachycardia (increased heart rate)
- Palpitations
- Increased blood pressure
- Weight loss
- Irritability and mood swings
- Tremor
- Increased sweating (hyperhidrosis)
- Rash or pruritus (itching)
- Upper respiratory tract infection
- Arthralgia (joint pain)
Uncommon (affects 1 to 10 in 1,000 people)
- Psychotic symptoms (hallucinations, paranoia)
- Depressed mood
- Suicidal ideation
- Dyskinesia (involuntary movements)
- Chest pain
- Dyspnea (shortness of breath)
- Blurred vision
- Muscle cramps
- Elevated liver enzymes
- Alopecia (hair loss)
Rare (affects fewer than 1 in 1,000 people)
- Angina pectoris, cardiac arrhythmias
- Sudden cardiac death (in patients with pre-existing structural heart defects)
- Cerebrovascular events (stroke, cerebral vasculitis)
- Raynaud's phenomenon (peripheral vasospasm)
- Neuroleptic malignant syndrome (NMS)
- Seizures
- Hepatotoxicity
- Erythema multiforme and other serious skin reactions
- Thrombocytopenia, leukopenia
- Priapism (prolonged, painful erection)
If you experience any serious side effects, particularly chest pain, severe headache, vision changes, fainting, signs of psychosis, or suicidal thoughts, seek immediate medical attention. Mild side effects such as decreased appetite and initial insomnia often improve within the first 2-4 weeks of treatment. If side effects persist and are bothersome, consult your prescribing physician about dose adjustment, timing changes, or alternative formulations.
You can help improve drug safety by reporting any side effects you experience. In the EU, side effects can be reported through the national pharmacovigilance systems. In the UK, reports can be made via the Yellow Card Scheme. In the US, adverse events can be reported to the FDA's MedWatch program. Healthcare professionals are encouraged to report all suspected adverse reactions.
How Should You Store Methylphenidate Generis?
Store Methylphenidate Generis at room temperature (below 25°C/77°F), in the original packaging, protected from moisture and direct light. Keep out of reach of children and in a secure location, as this is a controlled substance with abuse potential.
Proper storage of Methylphenidate Generis is essential both for maintaining the medication's efficacy and for preventing unauthorized access, given its status as a controlled substance. Follow these detailed storage guidelines:
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Avoid exposure to excessive heat or freezing temperatures, as these can compromise the integrity of the osmotic-release tablet mechanism.
- Moisture protection: Keep the tablets in their original blister packaging until use. The extended-release formulation is sensitive to moisture, which can affect the osmotic-release system.
- Light protection: Store away from direct sunlight and strong artificial light.
- Security: Because methylphenidate is a controlled substance, it should be stored in a secure location that is not easily accessible to others, particularly children, adolescents, and individuals with a history of substance abuse.
- Disposal: Do not flush unused medication down the toilet or throw it in household waste. Return unused or expired tablets to a pharmacy for proper disposal through an authorized take-back program.
Check the expiry date printed on the packaging. Do not use Methylphenidate Generis after the expiry date, even if the tablets appear unchanged. The controlled-release mechanism may not function correctly in expired tablets, potentially leading to erratic drug release.
What Does Methylphenidate Generis Contain?
Each Methylphenidate Generis 18 mg extended-release tablet contains 18 mg of methylphenidate hydrochloride as the active ingredient, delivered via an osmotic-release oral system (OROS) with inactive ingredients including cellulose, polyethylene oxide, and iron oxide pigments.
Understanding the full composition of Methylphenidate Generis is important for patients with allergies or sensitivities to specific excipients. The tablet is a sophisticated pharmaceutical delivery system consisting of multiple layers designed to provide controlled drug release.
Active ingredient: Methylphenidate hydrochloride 18 mg per extended-release tablet.
Excipients (inactive ingredients): The extended-release tablet contains the following inactive ingredients that form the osmotic-release system:
- Tablet core: Cellulose acetate, hypromellose, phosphoric acid, poloxamer, polyethylene oxide, povidone, sodium chloride, stearic acid
- Overcoating: Hypromellose, lactose monohydrate, macrogol, titanium dioxide (E171), triacetin
- Color coating: Hypromellose, macrogol, yellow iron oxide (E172) — gives the 18 mg tablet its characteristic yellow-brown color
- Clear coating: Cellulose acetate, macrogol
- Printing ink: Iron oxide black (E172), propylene glycol, hypromellose
Appearance: The 18 mg tablet is typically a yellow-brown, round, biconvex tablet printed with "alza 18" or a similar identification marking. A small laser-drilled hole is visible on one end of the tablet — this is the delivery orifice through which the active ingredient is released.
Methylphenidate Generis contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. The amount of lactose in each tablet is typically small, but patients with known lactose sensitivity should discuss this with their physician or pharmacist.
Frequently Asked Questions
Methylphenidate Generis is an extended-release stimulant medication used primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older, adolescents, and adults. It may also be prescribed for narcolepsy. It helps improve attention, reduce impulsivity, and control hyperactive behavior as part of a comprehensive ADHD treatment program that typically includes behavioral therapy, educational support, and psychological counseling.
Methylphenidate Generis uses an osmotic-release oral system (OROS) technology. The tablet has an outer coating that provides an initial dose of methylphenidate within the first hour. Inside, an osmotic pump gradually pushes the remaining medication through a laser-drilled opening in the tablet over 10-12 hours. This provides steady therapeutic levels throughout the day with a single morning dose, mimicking the effect of taking three separate immediate-release doses.
No, absolutely not. Methylphenidate Generis extended-release tablets must be swallowed whole with water. Crushing, chewing, splitting, or dissolving the tablet destroys the controlled-release mechanism and results in the immediate release of the entire 18 mg dose at once, which can lead to dangerously high blood levels, increased side effects, and potential overdose symptoms. If you have difficulty swallowing tablets, speak with your physician about alternative formulations.
The most common side effects include decreased appetite (which may lead to weight loss), insomnia (difficulty falling asleep), headache, dry mouth, and nervousness. These effects are typically dose-dependent and often improve during the first 2-4 weeks of treatment. Decreased appetite is most noticeable during the middle of the day, and many patients find their appetite returns in the evening. If side effects are persistent or bothersome, your physician can adjust the dose or timing.
Methylphenidate has a recognized potential for abuse and psychological dependence when misused. However, when taken as prescribed under medical supervision for ADHD, the risk of addiction is significantly lower. The extended-release formulation further reduces abuse potential because it provides a gradual, controlled release rather than a rapid spike in brain drug levels. Research published in peer-reviewed journals suggests that appropriate ADHD treatment with stimulant medication may actually reduce the risk of developing substance use disorders later in life compared to untreated ADHD.
The outer coating begins releasing methylphenidate within 1-2 hours after ingestion. The full therapeutic effect of the extended-release system develops over 2-4 hours, and the medication continues working for approximately 10-12 hours. While symptom improvement can be noticed from the first dose, optimal therapeutic benefit for ADHD often requires several weeks of consistent use and dose optimization to find the right individual dose.
References
- European Medicines Agency (EMA). Methylphenidate hydrochloride — Summary of Product Characteristics. EMA/CHMP. Available at: www.ema.europa.eu. Accessed January 2026.
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. Updated 2024. Available at: www.nice.org.uk/guidance/ng87.
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd list, 2023. Geneva: World Health Organization; 2023.
- Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews. 2015;(11):CD009885. doi:10.1002/14651858.CD009885.pub2.
- Food and Drug Administration (FDA). Methylphenidate hydrochloride extended-release tablets — Prescribing Information. FDA Reference ID. Available at: www.fda.gov.
- British National Formulary (BNF). Methylphenidate hydrochloride. NICE/BNF. Updated 2025. Available at: bnf.nice.org.uk.
- Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews. 2021;128:789-818. doi:10.1016/j.neubiorev.2021.01.022.
- Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878-885. doi:10.1111/jcpp.12164.
- Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015-1027. doi:10.1097/chi.0b013e3180686d7e.
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specializing in clinical pharmacology, psychiatry, and neurology. Our team follows strict editorial standards based on the GRADE evidence framework, ensuring that all medical information is accurate, up-to-date, and evidence-based.
All medical claims are supported by peer-reviewed research from sources including EMA, FDA, WHO, NICE, Cochrane Reviews, and major medical journals.
iMedic receives no pharmaceutical company funding. Our editorial content is completely independent with no commercial influence on our recommendations.
All medication articles are reviewed and updated at least annually, or sooner when significant new evidence, safety alerts, or regulatory changes emerge.
This page meets the highest international accessibility standards, ensuring medical information is available to all users regardless of ability.